Revenue and margins
Revenue was $9.4M, down 20.4% from $11.8M in the same period a year earlier, which ended Sep 30, 2025. (SEC XBRL company facts, 10-Q, Nov 13, 2026)
The net loss was $55.7M. (SEC XBRL company facts, 10-Q, Nov 13, 2026)
Balance sheet
Cash was $34.7M at Sep 30, 2026, against $39.3M at Jun 30, 2026. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)
Shares outstanding were 34.2 million, against 34.1 million at Jun 30, 2026, a rise of 0.2%. (SEC XBRL company facts, 10-Q, Nov 13, 2026)
At its recent quarterly burn of $64.2M, that cash lasts about 1.6 months, by our estimate from its XBRL cash flows. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)
The stock
The Nasdaq screener puts its market value at $1.3B. (Nasdaq stock screener, Nov 13, 2026)
State Street Corp passes 5.0% of Nektar Therapeutics
In a Schedule 13G filed Nov 10, 2026, State Street Corp reported 1.8 million shares of Nektar Therapeutics (NKTR) as of Sep 30, 2026, 5.2% of the class. (SEC EDGAR, SCHEDULE 13G, Nov 10, 2026)
Follow it up
The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/NKTR)
The filing on SEC EDGAR. (sec.gov)
Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.